

Press Release 21 April 2026

Granted Patent in Japan - Biomarker for prediction of chemotherapy induced peripheral neuropathy

VibroSense Dynamics AB (“VibroSense”) has been granted a patent in Japan on a Biomarker to predict the risk of developing permanent nerve damage caused by chemotherapy (CIPN) at treatment of cancer.

The granted patent claims in Japan correspond to those previously granted by the European Patent Office (EPO). The patent strengthens the company’s intellectual property protection and complements existing safeguards including encrypted algorithms in the software of the company’s hand and foot instruments.

“It is well known that the nervous system is affected by chemotherapy, with a significant risk to get chronic nerve damage. Many treatments also have to be discontinued prematurely as a result of nerve damage becoming too severe. With our new discovery, we can help doctors and nurses identify those patients having an increased risk of developing nerve damage, making it possible to personalize treatment to the individual”, says Toni Speidel, CEO of VibroSense Dynamics AB.

ABOUT CIPN

CIPN are nerve damages caused by certain cytotoxic agents. It most commonly affects sensory nerves in the hands and feet, but can also cause motor and autonomic symptoms. CIPN is one of the most dose-limiting side effects in cancer therapy. Approximately 20–30 % of patients receiving neurotoxic chemotherapy develop chronic nerve damage. Japan is one of the world’s most cancer-affected nations, with among the highest incidences of gastric cancer, colorectal cancer and lung cancer globally.

Lung cancer is the most common cancer in both the EU and Asia, especially among men. Smoking is the main risk factor. Breast cancer is the most common cancer in women globally. Incidence is increasing in both the Western world and parts of Asia, especially in urbanized areas. Colorectal cancer is the third most common cancer globally and is increasing in younger age groups, especially in Asia where Western diets are becoming more common. For these three cancers, the incidence is estimated¹ to be around 5.6 million new cases per year in the EU and Asia¹.

¹ Source GLOBOCAN, Eurostat, World Cancer Research Fund, RCC Knowledge

For more information, please contact:

Toni Speidel, CEO VibroSense Dynamics AB

Tel: +46 40 88 026

Email: info@vibrosense.com

www.vibrosense.se

About VibroSense Dynamics AB (publ)

VibroSense Dynamics AB (publ) develops and sells medical devices and services to facilitate diagnosis of nerve damage in the hands and feet. The method is based on measuring and quantifying the ability to perceive vibrations applied to the skin at multiple frequencies. The company's customers include diabetes clinics, occupational health providers, hospitals, primary care centers, and researchers.

Our vision that the company's products shall become a standard tool in all neurological examinations, to detect early signs of sensory changes so that patients and healthcare providers can take preventive action to avoid, reduce, or delay the onset of nerve damage in the hands and feet.